Shuai Li | Biology and Life Sciences | Innovative Research Award

Published on by Innovation Technologist

Innovative Research Award

Shuai Li
Regeneron, United States
Shuai Li
Affiliation Regeneron
Country United States
Scopus ID 60597499200
Documents 6
Citations 221
h-index 4
Subject Area Biology and Life Sciences
Event Global Innovation Technologist Awards
ORCID 0000-0002-1537-3956

The Innovative Research Award recognizes the scholarly and scientific contributions of Shuai Li, a researcher associated with Regeneron and previously affiliated with Duke University. Li has contributed to interdisciplinary research spanning synthetic biology, metabolic engineering, supramolecular chemistry, and automated bioprocess technologies. The research portfolio demonstrates a combination of experimental innovation, engineering methodology, and translational biological applications within the broader field of biology and life sciences.[1]

Abstract

Shuai Li has developed a multidisciplinary academic profile integrating biological engineering, synthetic biology, supramolecular chemistry, and automation systems for laboratory applications. Published works include contributions to metabolic engineering in Escherichia coli, chiral molecular assemblies, CRISPR-associated biological systems, and open-source laboratory automation. The body of work reflects ongoing efforts to optimize biological production systems, enhance molecular recognition strategies, and improve accessibility to bioprocess instrumentation.[2][3]

Keywords

Synthetic Biology; Metabolic Engineering; Bioprocess Automation; Supramolecular Chemistry; CRISPR Systems; NADPH Flux; Chiroptical Switches; Biological Engineering; Automated Sampling Systems; Life Sciences Research.

Introduction

Contemporary life sciences research increasingly depends upon interdisciplinary approaches that integrate chemistry, engineering, automation, and computationally informed biological experimentation. Shuai Li’s scholarly contributions reflect this evolving research landscape through work involving engineered microbial systems, supramolecular interfaces, and laboratory automation platforms.[4]

Li completed academic training at Shandong University and the Institute of Chemistry of the Chinese Academy of Sciences before continuing research activities at Duke University. These educational and research experiences contributed to a broad methodological background that spans chemical sciences and biotechnology-oriented engineering disciplines.[1]

Research Profile

The Scopus author profile associated with Shuai Li reports 221 citations across multiple indexed documents and an h-index of 4, indicating measurable academic engagement and scholarly visibility within biotechnology and chemistry-related research communities.[1]

Research topics explored by Li include metabolic pathway optimization, enzyme regulation, supramolecular assembly, CRISPR/Cas systems, and automated sampling technologies for bioreactors. Publications demonstrate collaborations across academic laboratories and interdisciplinary scientific environments.[5]

  • Research specialization in synthetic biology and metabolic engineering.
  • Contributions to supramolecular and chiral chemistry methodologies.
  • Development of low-cost automated laboratory technologies.

Research Contributions

Among Li’s notable contributions is the development of the BioSamplr, an open-source automated sampling system designed for bioreactors. The platform aimed to provide a lower-cost alternative for laboratory sampling automation, thereby increasing accessibility for smaller research laboratories and educational institutions.[2]

Li also contributed to research focused on improving NADPH flux and xylitol biosynthesis in engineered E. coli systems through dynamic regulatory control strategies. This work addressed feedback regulation mechanisms and metabolic optimization relevant to industrial biotechnology applications.[3]

Additional studies investigated CRISPR-associated endonuclease complexes and their effects on self-targeting spacer stability. These findings contributed to understanding microbial genome regulation and CRISPR system functionality.[6]

In the field of supramolecular chemistry, Li co-authored studies examining chiroptical switches, chiral metallogels, and self-assembled polydiacetylene systems for enantioselective recognition. These works demonstrated applications of molecular self-assembly and chirality transfer in advanced chemical systems.[7][8]

Publications

  1. BioSamplr: An open source, low cost automated sampling system for bioreactors — HardwareX (2021).
  2. Dynamic control over feedback regulatory mechanisms improves NADPH flux and xylitol biosynthesis in engineered E. coli — Metabolic Engineering (2021).
  3. Escherichia coli Cas1/2 Endonuclease Complex Modifies Self-Targeting CRISPR/Cascade Spacers Reducing Silencing Guide Stability — ACS Synthetic Biology (2020).
  4. Supramolecular chiroptical switches — Chemical Society Reviews (2020).
  5. Self-Assembled Polydiacetylene Vesicle and Helix with Chiral Interface for Visualized Enantioselective Recognition of Sulfinamide — ACS Applied Materials & Interfaces (2017).

Research Impact

The academic impact of Li’s work is reflected through citations, interdisciplinary collaborations, and publication in peer-reviewed journals covering biotechnology, synthetic biology, materials science, and supramolecular chemistry. Research outputs have relevance for both academic investigation and industrial biotechnology applications.[3][7]

The integration of engineering principles with biological systems research has contributed to emerging methodologies in automated experimentation and metabolic pathway optimization. Such interdisciplinary work supports broader scientific efforts aimed at improving efficiency, reproducibility, and accessibility in laboratory research environments.[2]

Award Suitability

Shuai Li’s multidisciplinary research background aligns with the objectives of the Global Innovation Technologist Awards, which recognize scientific and technological advancements with measurable academic and practical significance. Contributions spanning metabolic engineering, CRISPR research, supramolecular chemistry, and open-source automation technologies demonstrate consistent engagement with innovation-oriented scientific inquiry.[1]

The combination of peer-reviewed publications, measurable citation performance, and interdisciplinary technical expertise supports recognition within the field of biology and life sciences. Li’s work illustrates the integration of engineering design principles with biological and chemical sciences to address contemporary research challenges.[4]

Conclusion

The scholarly profile of Shuai Li reflects interdisciplinary scientific engagement across synthetic biology, supramolecular chemistry, and laboratory engineering technologies. Through publications in recognized journals and contributions to biological automation systems, Li has participated in research initiatives with relevance to modern biotechnology and life sciences. The body of work demonstrates methodological diversity, collaborative scientific activity, and continuing participation in innovation-oriented academic research.[1][2]

References

  1. Elsevier. (n.d.). Scopus author details: Shuai Li, Author ID 60597499200. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=60597499200
  2. Li, S. et al. (2021). BioSamplr: An open source, low cost automated sampling system for bioreactors. HardwareX.
    https://doi.org/10.1016/j.ohx.2021.e00177
  3. Li, S. et al. (2021). Dynamic control over feedback regulatory mechanisms improves NADPH flux and xylitol biosynthesis in engineered E. coli. Metabolic Engineering.
    https://doi.org/10.1016/j.ymben.2021.01.005
  4. ORCID. (n.d.). Shuai Li ORCID profile and educational background.
    https://orcid.org/0000-0002-1537-3956
  5. Crossref Metadata Search. (n.d.). Publication metadata associated with Shuai Li.
  6. Li, S. et al. (2020). Escherichia coli Cas1/2 Endonuclease Complex Modifies Self-Targeting CRISPR/Cascade Spacers Reducing Silencing Guide Stability. ACS Synthetic Biology.
    https://doi.org/10.1021/acssynbio.0c00398
  7. Li, S. et al. (2020). Supramolecular chiroptical switches. Chemical Society Reviews.
    https://doi.org/10.1039/d0cs00191k
  8. Li, S. et al. (2017). Alanine-Based Chiral Metallogels via Supramolecular Coordination Complex Platforms: Metallogelation Induced Chirality Transfer. Journal of the American Chemical Society.
    https://doi.org/10.1021/jacs.7b10769

Dolores Di Vizio | Biochemistry | Best Researcher Award

Published on by Innovation Technologist

Prof. Dr. Dolores Di Vizio | Biochemistry | Best Researcher Award

Professor at Cedars-Sinai Medical Center | United States

Dr. Dolores Di Vizio is a globally recognized physician-scientist whose research has significantly advanced the fields of cancer biology, extracellular vesicles (EVs), and translational oncology. She holds multiple academic positions at Cedars-Sinai Medical Center and plays a leading role in international scientific organizations. Dr. Di Vizio is best known for pioneering the discovery of large oncosomes, a novel type of extracellular vesicle implicated in cancer progression and metastasis.

Publication Profile 

Scopus

Educational Background 

Dr. Di Vizio earned both her M.D. and Ph.D. degrees from the University of Naples Federico II in Italy. Following her graduate education, she completed postdoctoral training at Harvard Medical School, where she honed her expertise in molecular and cancer biology, laying the foundation for her later groundbreaking work in EVs and cancer metastasis.

Professional Experience 

Dr. Di Vizio is a Professor in the Departments of Surgery, Pathology & Laboratory Medicine, and Biomedical Sciences at Cedars-Sinai Medical Center in Los Angeles. She also serves as Co-Director of the Cancer Biology Program at the Samuel Oschin Comprehensive Cancer Institute. Her international presence includes visiting faculty positions at Yonsei University in Korea, the University of Calabria in Italy, and IRCCS Regina Elena in Italy. Prior to her tenure at Cedars-Sinai, she held a faculty position at Harvard Medical School. Her editorial influence is substantial, serving as Deputy Editor of the Journal of Extracellular Vesicles and sitting on the editorial boards of prominent journals such as Oncotarget, Biomedicines, and Frontiers in Oncology. Additionally, she has organized and chaired major scientific conferences including the Gordon Research Conference and the International Society for Extracellular Vesicles (ISEV) meetings in 2021 and 2023.

Research Interests 

Dr. Di Vizio’s research centers on the biology of extracellular vesicles, particularly large oncosomes, and their role in tumor dissemination, with a focus on prostate cancer. She investigates the molecular and cellular mechanisms driving cancer metastasis and signal transduction, including cytoskeletal remodeling and intercellular communication. Her work also emphasizes translational research, with a goal of developing EV-based diagnostic tools and therapeutic strategies for advanced cancers.

Awards and Honors 

Throughout her career, Dr. Di Vizio has secured over $10 million in competitive research funding from prestigious agencies including the National Institutes of Health (NIH), Department of Defense (DoD), Avon Foundation, and the American Italian Cancer Foundation (AICF). She has been an invited speaker at more than 70 national and international institutions and high-profile events, such as Nature Webinars, Keystone Symposia, and AACR meetings. She has also served as a reviewer and panelist for NIH study sections, the DoD Prostate Cancer Program, and the European Research Council (ERC). Her contributions to mentorship and training are equally impressive, with leadership roles in NIH T32, R25, and CTSI-supported programs and mentorship roles in DoD and SPORE-funded initiatives.

Publications 

  1. Title: Extracellular vesicle heterogeneity through the lens of multiomics
    Year: 2025

  2. Title: Roadblocks of Urinary EV Biomarkers: Moving Toward the Clinic
    Year: 2025

  3. Title: Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
    Year: 2025

  4. Title: A class of large cell-like extracellular vesicles: Extracellular vesicles
    Year: 2025
    Citations: 3

  5. Title: Mechanisms governing lineage plasticity and metabolic reprogramming in cancer
    Year: 2025
    Citations: 3

Conclusion 

Dr. Dolores Di Vizio is an internationally respected leader in cancer research whose pioneering contributions to extracellular vesicle biology have reshaped current understanding of tumor progression and metastasis. Her dedication to translational science, strong record of mentorship, and active leadership in global scientific communities position her as a standout figure in contemporary oncology research. She is exceptionally well-qualified for recognition through high-level research awards, embodying a career defined by scientific innovation, educational commitment, and impactful interdisciplinary collaboration.